Kezar Life Sciences (KZR) Liabilities and Shareholders Equity (2021 - 2025)
Historic Liabilities and Shareholders Equity for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $97.7 million.
- Kezar Life Sciences' Liabilities and Shareholders Equity fell 4044.22% to $97.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $476.8 million, marking a year-over-year decrease of 3762.32%. This contributed to the annual value of $144.7 million for FY2024, which is 3460.26% down from last year.
- Per Kezar Life Sciences' latest filing, its Liabilities and Shareholders Equity stood at $97.7 million for Q3 2025, which was down 4044.22% from $109.1 million recorded in Q2 2025.
- Over the past 5 years, Kezar Life Sciences' Liabilities and Shareholders Equity peaked at $317.5 million during Q2 2022, and registered a low of $97.7 million during Q3 2025.
- In the last 5 years, Kezar Life Sciences' Liabilities and Shareholders Equity had a median value of $199.1 million in 2024 and averaged $202.8 million.
- As far as peak fluctuations go, Kezar Life Sciences' Liabilities and Shareholders Equity soared by 13284.62% in 2022, and later tumbled by 4044.22% in 2025.
- Over the past 5 years, Kezar Life Sciences' Liabilities and Shareholders Equity (Quarter) stood at $217.9 million in 2021, then skyrocketed by 37.46% to $299.6 million in 2022, then dropped by 26.15% to $221.2 million in 2023, then crashed by 34.6% to $144.7 million in 2024, then crashed by 32.45% to $97.7 million in 2025.
- Its Liabilities and Shareholders Equity stands at $97.7 million for Q3 2025, versus $109.1 million for Q2 2025 and $125.3 million for Q1 2025.